431 related articles for article (PubMed ID: 26660282)
1. Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study.
Connors LH; Sam F; Skinner M; Salinaro F; Sun F; Ruberg FL; Berk JL; Seldin DC
Circulation; 2016 Jan; 133(3):282-90. PubMed ID: 26660282
[TBL] [Abstract][Full Text] [Related]
2. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
[TBL] [Abstract][Full Text] [Related]
3. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.
Grogan M; Scott CG; Kyle RA; Zeldenrust SR; Gertz MA; Lin G; Klarich KW; Miller WL; Maleszewski JJ; Dispenzieri A
J Am Coll Cardiol; 2016 Sep; 68(10):1014-20. PubMed ID: 27585505
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
Gagliardi C; Perfetto F; Lorenzini M; Ferlini A; Salvi F; Milandri A; Quarta CC; Taborchi G; Bartolini S; Frusconi S; Martone R; Cinelli MM; Foffi S; Reggiani MLB; Fabbri G; Cataldo P; Cappelli F; Rapezzi C
Eur J Heart Fail; 2018 Oct; 20(10):1417-1425. PubMed ID: 30070416
[TBL] [Abstract][Full Text] [Related]
5. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.
Hanson JLS; Arvanitis M; Koch CM; Berk JL; Ruberg FL; Prokaeva T; Connors LH
Circ Heart Fail; 2018 Feb; 11(2):e004000. PubMed ID: 29449366
[TBL] [Abstract][Full Text] [Related]
6. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.
Mints YY; Doros G; Berk JL; Connors LH; Ruberg FL
ESC Heart Fail; 2018 Oct; 5(5):772-779. PubMed ID: 29916559
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan.
Yamada T; Takashio S; Arima Y; Nishi M; Morioka M; Hirakawa K; Hanatani S; Fujisue K; Yamanaga K; Kanazawa H; Sueta D; Araki S; Usuku H; Nakamura T; Suzuki S; Yamamoto E; Ueda M; Kaikita K; Tsujita K
ESC Heart Fail; 2020 Oct; 7(5):2829-2837. PubMed ID: 32672425
[TBL] [Abstract][Full Text] [Related]
8. Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy.
Yamamura S; Izumiya Y; Ishida T; Onoue Y; Kimura Y; Hanatani S; Araki S; Fujisue K; Sueta D; Kanazawa H; Takashio S; Usuku H; Sugamura K; Sakamoto K; Yamamoto E; Yamamuro M; Yasuda H; Kojima S; Kaikita K; Hokimoto S; Ogawa H; Tsujita K
Heart Vessels; 2017 Jun; 32(6):708-713. PubMed ID: 27882404
[TBL] [Abstract][Full Text] [Related]
9. Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis.
Yunis A; Doros G; Luptak I; Connors LH; Sam F
Am J Cardiol; 2019 Jul; 124(1):122-130. PubMed ID: 31053293
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study.
Tini G; Milani P; Zampieri M; Caponetti AG; Fabris F; Foli A; Argirò A; Mazzoni C; Gagliardi C; Longhi S; Saturi G; Vergaro G; Aimo A; Russo D; Varrà GG; Serenelli M; Fabbri G; De Michieli L; Palmiero G; Ciliberti G; Carigi S; Sessarego E; Mandoli GE; Ricci Lucchi G; Rella V; Monti E; Gardini E; Bartolotti M; Crotti L; Merli E; Mussinelli R; Vianello PF; Cameli M; Marzo F; Guerra F; Limongelli G; Cipriani A; Perlini S; Obici L; Perfetto F; Autore C; Porto I; Rapezzi C; Sinagra G; Merlo M; Musumeci B; Emdin M; Biagini E; Cappelli F; Palladini G; Canepa M
Eur J Heart Fail; 2023 Jun; 25(6):845-853. PubMed ID: 36907828
[TBL] [Abstract][Full Text] [Related]
12. Wild-Type Transthyretin Amyloid Cardiomyopathy: A Missed Cause of Heart Failure With Preserved Ejection Fraction With Evolving Treatment Implications.
Liu PP; Smyth D
Circulation; 2016 Jan; 133(3):245-7. PubMed ID: 26660283
[No Abstract] [Full Text] [Related]
13. Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and
Ochi Y; Kubo T; Nakashima Y; Baba Y; Hirota T; Yamasaki N; Yamashita T; Ueda M; Ando Y; Kitaoka H
J Cardiol; 2020 Jan; 75(1):12-19. PubMed ID: 31324572
[TBL] [Abstract][Full Text] [Related]
14. Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis.
Rubin J; Steidley DE; Carlsson M; Ong ML; Maurer MS
J Card Fail; 2018 Aug; 24(8):504-511. PubMed ID: 30010028
[TBL] [Abstract][Full Text] [Related]
15. Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis.
Rosenbaum AN; AbouEzzeddine OF; Grogan M; Dispenzieri A; Kushwaha S; Clavell A; Daly RC; Edwards BS
Transplantation; 2018 Nov; 102(11):1909-1913. PubMed ID: 29677073
[TBL] [Abstract][Full Text] [Related]
16. Incidence and predictors of worsening heart failure in patients with wild-type transthyretin cardiac amyloidosis.
Ladefoged BT; Dybro A; Dahl Pedersen AL; Rasmussen TB; Vase HØ; Clemmensen TS; Gillmore J; Poulsen SH
ESC Heart Fail; 2022 Oct; 9(5):2978-2987. PubMed ID: 35733407
[TBL] [Abstract][Full Text] [Related]
17. The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis.
Driggin E; Maurer MS
Clin Cardiol; 2020 Feb; 43(2):171-178. PubMed ID: 31825134
[TBL] [Abstract][Full Text] [Related]
18. A new staging system for cardiac transthyretin amyloidosis.
Gillmore JD; Damy T; Fontana M; Hutchinson M; Lachmann HJ; Martinez-Naharro A; Quarta CC; Rezk T; Whelan CJ; Gonzalez-Lopez E; Lane T; Gilbertson JA; Rowczenio D; Petrie A; Hawkins PN
Eur Heart J; 2018 Aug; 39(30):2799-2806. PubMed ID: 29048471
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm.
Inomata T; Tahara N; Nakamura K; Endo J; Ueda M; Ishii T; Kitano Y; Koyama J
ESC Heart Fail; 2021 Aug; 8(4):2647-2659. PubMed ID: 34137515
[TBL] [Abstract][Full Text] [Related]
20. Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.
Narotsky DL; Castano A; Weinsaft JW; Bokhari S; Maurer MS
Can J Cardiol; 2016 Sep; 32(9):1166.e1-1166.e10. PubMed ID: 27568874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
